GlassScriptPhysician profile
Dapeng Fan
NPI 1619116597
$670.64
in general payments reported to CMS, 2019-2025
11 companies · $22.33 in 2025
The $22.33 reported for 2025 was less than what a typical Anesthesiology provider received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $95.16 · 2021: $50.72 · 2022: $18.00 · 2023: $260 · 2024: $94.75 · 2025: $22.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $377.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $223.11 | 2023-2024 | Stelara |
| Comsort, INC | $100.00 | 2019 | |
| Ambu INC. | $95.16 | 2020 | |
| Intercept Pharmaceuticals, INC. | $66.91 | 2021-2023 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $43.80 | 2023 | Linzess |
| Qol Medical, LLC | $37.33 | 2022-2024 | Sucraid |
| Merck Sharp & Dohme LLC | $31.70 | 2019-2024 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $19.73 | 2021 | |
| Lilly USA, LLC | $19.14 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $16.93 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dapeng Fan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.